Skip to main content
main-content

05.02.2019 | Chronische lymphatische Leukämie | International Research Highlight | Onlineartikel

International Research Highlight

Haematological cancer: Alliance to iLLUMINATE the chemo-free sign

Autor:
Diana Romero
Treatment regimens for patients with chronic lymphocytic leukaemia (CLL) increasingly include targeted agents (such as the inhibitor of BTK ibrutinib or the anti-CD20 antibodies rituximab and obinutuzumab) rather than cytotoxic agents (for example, the DNA alkylating agents chlorambucil and bendamustine). New evidence supporting benefit with targeted therapies was presented at the 2018 Annual Meeting of the American Society of Hematology (ASH).

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weiterführende Themen


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise